Xenetic Biosciences, Inc. (XBIO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-1576.3%

-$30.41

vs $2.06 price

Levered DCF

-$31.56

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-36.91

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.37×	-1.55×	-1.27×	-0.63×	-2.39×	-1.2×	-0.26×	-2.04×
P/B	0.5×	1.02×	0.54×	0.3×	0.72×	1.07×	0.24×	1.5×
P/S	1.24×	2.46×	2.08×	2.38×	11.42×	29.84×	240.69×	0×
EV / EBITDA	1.56×	0×	0.9×	1.39×	0.88×	-0.34×	0.65×	-1.97×
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%
Operating margin	-95.2%	-168.2%	-177.8%	-393.6%	-495.1%	-3189.8%	-75511.7%	0.0%
Net margin	-90.1%	-158.4%	-162.8%	-383.9%	-486.4%	-2493.1%	-74856.6%	0.0%
Current ratio	8.32×	7.37×	11.84×	12.72×	13.18×	13.2×	7.84×	0.75×
Debt / equity	0×	0×	0×	0×	0×	0.01×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	-301.53×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-36.2%	-65.9%	-42.2%	-48.0%	-30.7%	-89.2%	-74.2%	-73.6%
Return on invested capital	-38.3%	-70.0%	-46.1%	-49.2%	-31.2%	-89.5%	-63.9%	-56.7%
Return on assets	-32.1%	-57.4%	-39.0%	-44.5%	-28.5%	-82.7%	-59.3%	-50.6%
Free cash flow yield	-61.9%	-45.8%	-78.0%	-127.0%	-35.7%	-32.7%	-155.8%	-43.5%
Earnings yield	-72.6%	-64.4%	-78.4%	-161.6%	-42.6%	-83.5%	-311.0%	-49.1%
Enterprise value	-$4.2M	-$15.6K	-$3.7M	-$9M	-$5M	$1.6M	-$6.2M	$14.3M
Net debt / EBITDA	2.94×	1.62×	2.17×	2.01×	3.25×	2.46×	1.08×	0.08×
Cash conversion cycle (days)	0	0	0	0	0	0	0	-21,543